Detecting and Excluding COVID-19 at Point of Need
- Funded by Foreign, Commonwealth & Development Office (FCDO), Wellcome Trust
- Total publications:11 publications
Grant number: 220764/Z/20/Z
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$1,163,416.24Funder
Foreign, Commonwealth & Development Office (FCDO), Wellcome TrustPrincipal Investigator
Dr. Joe FitchettResearch Location
United Kingdom, SenegalLead Research Institution
MologicResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
Innovation
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Rapid diagnostics have been identified by the WHO R&D Blueprint as a critical unmet need for the control of COVID-19 - particularly in the absence of a vaccine and proven antiviral agents. Our primary objective is to develop a low cost, high performance rapid test for the detection and exclusion of SARS-CoV-2, the causative virus of coronavirus disease 2019 (COVID-19). The technology will be made available in line with the Global Access Policy for Gavi-eligible countries that are most vulnerable to onward transmission of COVID-19 and of limited detection due to insufficient laboratory capacity. The RDT will be appropriate for assembly and manufacture with multiple quality-assured partners to meet demand.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC